- £156.80m
- £273.47m
- £20.31m
- 46
- 37
- 75
- 52
Annual balance sheet for Life Science Reit, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 166 | 45.6 | 14.3 | 5.57 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 3.16 | 4.13 | 4.25 | 3.05 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 169 | 53.7 | 21 | 12.1 |
| Long Term Investments | ||||
| Long Term Notes Receivable | ||||
| Other Long Term Assets | ||||
| Total Assets | 361 | 448 | 411 | 401 |
| Payable / Accrued | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 10.8 | 50.4 | 14.4 | 12.4 |
| Long Term Debt | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 10.8 | 128 | 127 | 138 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | 351 | 319 | 284 | 263 |
| Total Liabilities & Shareholders' Equity | 361 | 448 | 411 | 401 |
| Total Common Shares Outstanding |